Liraglutide: Scientific Profile

Publicado el 12 de julio de 2026 · Actualizado el 24 de agosto de 2026

Liraglutide (NN2211, CAS 204656-20-2) is an acylated analog of the human GLP-1 peptide, a GLP-1 receptor agonist designed for metabolic research. Its central mechanism is the activation of the GLP-1 receptor with a prolonged half-life thanks to a palmitoyl fatty acid chain. Material for laboratory research use only.

Liraglutide, identified by the development code NN2211 and CAS number 204656-20-2, is an analog of human glucagon-like peptide-1 (GLP-1) that has been widely studied in the field of metabolic and appetite-regulation research. It belongs to the class of incretins and, more specifically, to the family of GLP-1 receptor (GLP-1R) agonists. With a molecular formula C172H265N43O51 and an approximate molecular weight of 3751.2 g/mol, Liraglutide is a long-chain peptide molecule structurally derived from the native sequence of human GLP-1 in its active fragment GLP-1(7-37). It is distributed as material for laboratory research, and all the information that follows is offered in a strictly scientific and experimental framework.

From a structural standpoint, Liraglutide is built on the amino-acid backbone of GLP-1(7-37) with two key modifications that distinguish it from the endogenous peptide. The first is a substitution of the lysine residue at position 34 with arginine, a change that reduces the formation of unwanted acylation products during synthesis. The second, and the most decisive for its pharmacokinetic profile, is the incorporation of a sixteen-carbon fatty-acid chain (palmitic acid) attached to the lysine residue at position 26 through a glutamic-acid (gamma-glutamyl) spacer. This fatty-acid acylation is the design feature that defines the molecule: it allows Liraglutide to bind reversibly and non-covalently to serum albumin in the study models, which notably delays its degradation by the enzyme dipeptidyl peptidase-4 (DPP-4) and its renal elimination. The result is a considerably longer half-life than that of native GLP-1, whose duration of action is barely a few minutes. This lipidation-based prolongation strategy positions Liraglutide as a conceptual precursor of later, even longer-acting analogs.

The mechanism of action of Liraglutide centers on the selective activation of the GLP-1 receptor, a class B G protein-coupled receptor (GPCR) expressed in pancreatic beta cells, as well as in the central nervous system, the gastrointestinal tract, and other tissues. Upon binding to GLP-1R, Liraglutide stimulates the adenylate cyclase pathway, increasing intracellular levels of cyclic AMP (cAMP) and activating protein kinase A (PKA) and exchange factors such as Epac2. In the study models of the pancreatic beta cell, this signaling potentiates insulin secretion in a glucose-dependent manner, that is, the insulinotropic effect is manifested preferentially when glucose concentrations are elevated, which in preclinical models is associated with a low potential for hypoglycemia. Additionally, activation of GLP-1R has been linked in the research literature with suppression of glucagon secretion, slowing of gastric emptying, and, at the level of the hypothalamic nuclei that regulate satiety, with a reduction of food intake in animal models. These axes explain why Liraglutide has been used as an experimental tool both in studies of glucose homeostasis and in models of energy balance and body weight regulation.

As for its documented research applications, Liraglutide has served as a reference compound in numerous preclinical and clinical studies within the class of GLP-1R agonists. Research models have explored its influence on insulin sensitivity, beta-cell function, the neuronal circuits of appetite, and various cardiometabolic parameters. It has also been used as a comparator molecule in investigations into neuroprotection, given that GLP-1 receptors have been described in neuronal tissue and that several research groups have examined GLP-1R agonists in models of neurodegenerative diseases. Likewise, Liraglutide is a frequent reference point in peptide chemistry and pharmacokinetics work studying the effect of fatty-acid acylation on albumin binding and the prolongation of half-life, a design principle that has influenced the development of subsequent analogs.

The level of evidence supporting the characterization of Liraglutide is solid within its class: it is one of the best-studied molecules of the GLP-1 receptor agonist family, with an extensive body of preclinical literature and human clinical trials that have described its pharmacological profile. This degree of characterization sets it apart from many obscure or poorly studied research peptides. Nevertheless, all of this information is presented here exclusively for the purposes of scientific research and technical reference; the compound is offered as laboratory material, intended solely for experimental research and without any diagnostic or therapeutic application outside that context. Researchers working with Liraglutide should handle it in accordance with good laboratory practices, independently verify its identity and purity by appropriate analytical techniques, and consult the peer-reviewed primary literature when designing their experimental protocols.